Skip to main content
. Author manuscript; available in PMC: 2019 Apr 10.
Published in final edited form as: Ann Neurol. 2018 Apr 10;83(4):816–829. doi: 10.1002/ana.25212

Fig. 2. Detection of neurochemical abnormalities in MR spectra obtained from individuals with SCA at premanifest stage vs. healthy controls.

Fig. 2

MRS voxel locations and spectra (semi-LASER, TE=26 ms, TR=5 s, 64 transients) are shown from a single subject in each group; subjects with SCAs were at the premanifest stage (SARA ≤ 2.5). Arrows indicate type I error corrected significant group metabolite differences in each early SCA group compared to controls. [Abbreviations: Glc, glucose; Gln, glutamine; Glu, glutamate; mI, myo-inositol; tCho, total choline; tCr, total creatine; tNAA, total N-acetylaspartate; Tau, taurine].